Fresenius Medical Care AG & Co. KGaA
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Helen Giza
- Full Time Employees
- 108,165
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Address
- Else-KrOener Strasse 1 Bad Homburg HE Germany 61352
- IPO Date
- Sep 17, 1996
- CIK
- 0001333141
- Website
- freseniusmedicalcare.com
- Similar Companies
- Business
- Fresenius Medical Care AG & Co. KGaA, the world's leading provider of dialysis products and services, offers a comprehensive portfolio along the entire dialysis value chain, including dialysis machines such as the 2008T BlueStar and Liberty Select systems, dialyzers like Optiflux, reverse osmosis water purification systems, renal pharmaceuticals, therapeutic apheresis solutions, and related disposables and supplies; it operates approximately 3,700 dialysis clinics serving over 299,000 patients worldwide as of December 2024, with around 40 production sites across all continents and a dominant 38% market share in the US dialysis sector. Founded in 1996 through the merger of Fresenius AG's dialysis division and National Medical Care, the company maintains global headquarters in Bad Homburg vor der Höhe, Germany, North American headquarters in Waltham, Massachusetts, and regional hubs in Hong Kong for Asia-Pacific and Rio de Janeiro for Latin America; it focuses on chronic and acute kidney disease treatments for end-stage renal disease patients, primarily through outpatient centers, value-based care models, and care enablement services targeting nephrologists and healthcare providers in North America, Europe, Asia-Pacific, and Latin America. In recent developments, Fresenius Medical Care advances its FME Reignite strategy by investing EUR 312 million in September 2025 to increase ownership in Interwell Health, a renal value-based care leader, accelerating vertical integration following the 2022 merger of Cricket Health, Interwell Health, and Fresenius Health Partners; it divests select kidney disease laboratory testing assets of Spectra Laboratories to Quest Diagnostics in early 2025 to enhance operational efficiencies; and launches the FME Reignite strategy in June 2025 to strengthen core operations, drive innovation, and improve cash flow with planned annual capex of EUR 800 million to EUR 1 billion through 2030.
Company News
Fresenius Medical Care Reshapes China Portfolio for Long-Term Growth
Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Stock Has Consensus Price Target of $23.57 According to Brokerages
Fresenius Medical Care Refines China Commercial Strategy with a Focus on Long-Term Growth and Market Leadership
Tidal Investments LLC Buys 48,885 Shares of Fresenius Medical Care AG & Co. KGaA $FMS
Can Fresenius Medical's 5008X Rollout Drive the Next Growth Phase?
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Share Price Passes Above 200 Day Moving Average – Time to Sell?
3 Cheap International Stocks to Buy
Fresenius Medical Care AG & Co. KGaA Q2 Earnings Call Highlights
FMS Q2 Earnings Rise on Care Delivery, Revenues Miss, Margins Expand
Silicon Motion Showcases Next-Generation Storage Solutions for Agentic AI Applications at FMS 2026
Silicon Motion Showcases Next-Generation Storage Solutions for Agentic AI Applications at FMS 2026
Fresenius Medical Care AG (FMS) Q2 2026 Earnings Call Transcript
Fresenius Medical Care AG & Co. KGaA Q2 Earnings Call Highlights
Fresenius Medical Care Shares Drop After U.S. Treatment Volumes Fall Further
Kioxia Showcases Flash Storage Innovations for the AI Era at FMS 2026
Dialysis firm FMC's shares slide despite earnings beat as US volumes disappoint again
Fresenius Medical Care beats quarterly profit estimates, sticks to 2026 outlook
Silicon Motion Showcases Next-Generation Storage Solutions for Agentic AI Applications at FMS 2026
Marvell to Showcase Advanced AI Memory and Storage Infrastructure Portfolio for Agentic AI Inference at FMS 2026